Takeda Facing Trial Over Actos in California As Evidence Emerges That Exec’s Hid Risks in 2003 To Protect Sales

In 1999 the FDA approved a drug developed by Takeda Pharmaceuticals for the treatment of Type 2 diabetes. Actos, from the class of drugs known as thiazolidinediones is said to increase the sensitivity to insulin. Fourteen years later, the affects of this drug are presenting themselves.

In 2010, the FDA came out with a safety announcement concerning this drug:

[6-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. …The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.

Since this announcement was released, studies continue to confirm the ill-affects of this drug.

In June of 2011, the FDA published a “Drug Safety Communication” indicating that based on dosage; there is a 40% greater risk of developing bladder cancer than previously suggested in trial studies.

The communique also stated that the length of time the drug was administered also increased the risk of developing bladder cancer. These results came from a study that was conducted by Kaiser Permanente Northern California. The study supported by Takeda and required by the FDA also showed that the risk was higher for men than women.

In 2011, France and Germany pulled the drug from their markets and discontinued its use. Takeda took action and withdrew Actos from those markets. At this time, Actos is unrestricted and still used in the United States.

Bloomberg.com says that Takeda, Asia’s biggest drug maker, could face more than 10,000 claims that Actos causes bladder cancer. Bladder cancer is the fourth most common cancer amongst Americans.

Bloomberg also recently reported that evidence recently emerged showing that Takeda’s Exec’s were so concerned in 2003 about the effect a bladder cancer warning would have on sales that it survey doctors. Attorneys believe that Takeda decided to not warn based on the survey’s results. This should be a major issue in the first trial, which is set to commence in February in California.

We are your actos bladder cancer victim lawyer. If you or a family member have taken Actos for Type 2 Diabetes and have developed bladder cancer contact us for a consultation. We will work hard for you.